Ardelyx Trying To Rewrite Tenapanor’s Narrative: Less Side Effects, New Biomarker

Having regained full rights to the first-in-class NHE3 inhibitor from AstraZeneca, Ardelyx plans a Phase III study in IBS-C and a Phase IIb study in hyperphosphatasia related to kidney dialysis before year’s end.